Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Clinical lymphoma, myeloma & leukemia（2023）
摘要
Ixazomib is a feasible and effective maintenance option for prolonging PFS across this heterogeneous patient population.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要